MMP19 and type 2 diabetes mellitus: For both groups not on initial GLDT, this equalisation of initial treatment with statins and RASi could significantly reduce the standardised 5 year risk of MACE: by 2.1% (95% CI 1.2, 2.9) in the group with persistent type 2 diabetes and by 1.1% (95% CI 0.4, 1.9) in the remission group (Fig. 4).